AUTHORS
Francesca Palandri, MD, PhD, Andrew T Kuykendall, MD2, Aniket Bankar, MD, MSc, DM, MBBS3, Kristen Pettit, MD4, Joseph Shatzel, MD5, Jiri Mayer, MD6, Valentín García Gutiérrez I, MD7, Naveen Pemmaraju, MD8, Abdulraheem Yacoub, MD9, Harinder Gill, MBBS, MD10, Antonin Hlusi, MD11, Daniel Sasca, MD12, Peter E. Westerweel, MD, PhD13, Arturo Molina, MD, MS14, Phil Dinh15, Yu-Che Chung16, Alisa Harrigan17, Shining Wang, MD, PhD18, Alessandro Lucchesi, MD, PhD19
AFFILIATIONS
1 IRCCS Azienda Ospedaliero-Universitaria di Bologna – Institute of Hematology “L. and A. Seragnoli”, Bologna, Italy
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 University of Michigan Health, Ann Arbor, Michigan, United States
5 Oregon Health & Science University, Portland, Oregon, United States
6 University Hospital Brno and Masaryk University, Brno, Czech Republic
7 Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 University of Kansas Cancer Center, Westwood, Kansas, United States
10 Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, Hong Kong
11 Palacký University and University Hospital Olomouc, Olomouc, Czech Republic
12 Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany
13 Department of Hematology, Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
14 Protagonist Therapeutics, Inc., Newark, California, United States
15 Protagonist Therapeutics, Inc., Newark, California, United States
16 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
17 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
18 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
19 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
ABSTRACT
Introduction: PV is a myeloproliferative neoplasm characterized by the uncontrolled production of red blood cells, resulting in elevated hematocrit (Hct) and increased blood viscosity. Current standard of care (SOC) aims to achieve/maintain Hct <45% and includes phlebotomy (PHL) with/without cytoreductive therapies (CRTs), such as HU; however, many patients (pts) do not tolerate HU or may decline exposure to CRTs. Rusfertide is a first-in-class, self-administered, subcutaneous peptide that mimics the endogenous hormone hepcidin, the body’s principal regulator of iron homeostasis. In the phase 3 VERIFY trial (NCT05210790), rusfertide plus SOC met the primary endpoint (clinical response [absence of PHL eligibility]; p<0.0001) and all four key secondary endpoints (p<0.05 for each endpoint) versus placebo (PBO) plus SOC. Prior HU exposure was not required for VERIFY enrollment. This post hoc analysis from VERIFY evaluated clinical outcomes in pts with and without prior exposure to HU at baseline.
Methods: Pts with PV requiring frequent PHL with or without CRT to achieve and maintain Hct <45% were randomized 1:1 to receive once weekly rusfertide or PBO, plus SOC, from baseline to Week (Wk) 32 (part 1a). All pts received open-label rusfertide after Wk 32 (parts 1b and 2). Primary endpoint: proportion of pts achieving clinical response (absence of PHL eligibility) from Wks 20 to 32. Key secondary endpoints were the mean number of PHLs, proportion of pts with Hct <45%, and mean change in scores of the PROMIS Fatigue SF-8a T-Score and MFSAF version 4.0 patient reported outcome questionnaires from baseline to Wk 32.
Results: At data cutoff (May 27, 2025), 293 pts had been enrolled into part 1a; 161 pts had prior HU exposure and 132 had no prior HU; 114 pts continued to receive HU during the trial. Of 285 pts who received rusfertide in study parts 1a, 1b or 2, 154 had prior HU and 131 had no prior HU. Among pts with prior vs no prior HU, respectively, median PV duration was 3.6 vs 2.3 years, and 65% vs 24% had high-risk PV (age ≥60 years or thrombosis history). During Wks 20–32, among pts with prior HU, significantly more pts in the rusfertide plus SOC arm vs the PBO plus SOC arm, respectively, had a clinical response: 71% vs 33% of pts (p<0.0001). Similar results were seen in pts with no prior HU, with clinical response rates of 85% vs 33%, respectively (p<0.0001). Mean (standard deviation [SD]) number of PHLs from baseline to Wk 32 was lower with rusfertide vs PBO, respectively, regardless of prior HU use: 0.6 (1.3) vs 1.9 (1.6) in pts with prior HU, and 0.4 (0.9) vs 1.7 (1.4), in pts with no prior HU. A significantly higher number of pts maintained Hct <45% in the rusfertide vs PBO arms, respectively, between Wks 0–32, also regardless of prior HU: 56% vs 14% (p<0.0001) of pts with prior HU and 71% vs 15% (p<0.0001) of pts without prior HU. Mean (SD) change from baseline at Wk 32 in the PROMIS Fatigue SF-8a T-Score was greater with rusfertide vs PBO, respectively, in pts with or without prior HU, although the difference was more marked among pts with prior HU: −4.0 (7.8) vs 0.4 (7.7) compared with −3.8 (8.8) vs −2.8 (8.4) in pts with no prior HU. Mean (SD) change from baseline at Wk 32 in the MFSAF TSS7 was also greater with rusfertide vs PBO, respectively, in both subgroups: −3.4 (8.4) vs 0.2 (6.3) in pts with prior HU and −2.4 (7.6) vs −0.3 (5.1) in pts with no prior HU. Among all 285 pts who received rusfertide during the study, treatment-emergent adverse events (TEAEs) occurred in a comparable proportion of pts with (89%) or without (92%) prior HU. In pts with prior HU, the most common TEAEs (in >20% of pts) were anemia (27%), injection site (IS) erythema (24%), and fatigue (22%). In pts with no prior HU, the most common were IS erythema (31%), anemia (24%), IS pain (21%), and IS pruritus (21%). Non-melanoma skin cancers were reported in 5.6% of pts with and 1.4% of pts without prior HU. Grade 3–4 TEAEs were reported in 21% of pts with and 11% of pts without prior HU. Serious TEAEs occurred in 10% of pts with and 5% of pts without prior HU.
Conclusions: In this post hoc analysis of the phase 3 VERIFY trial, rusfertide demonstrated an efficacy benefit vs PBO, regardless of prior HU treatment, despite the prior HU group having a longer median disease duration and generally higher-risk PV. This alongside the tolerable safety profile, suggests that rusfertide may be a possible option early in the PV treatment algorithm.
DISCLOSURES
Francesca Palandri, MD, PhD: GlaxoSmithKline - Honoraria; Novartis - Honoraria; Amgen - Honoraria; Grifols - Honoraria; Incyte - Honoraria; Bristol Myers Squibb - Honoraria; AOP Health - Honoraria; Takeda - Honoraria; Sobi - Honoraria; Sanofi - Honoraria; GlaxoSmithKline - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Grifols - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); AOP Health - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony)